Ibex
AI-based cancer diagnostics for pathology, including Ibex Prostate Detect, assisting pathologists in detecting cancer and quantifying tissue features.
This is where the depth lives — everything below is evidence-graded
How the product is positioned
AI-based cancer diagnostics for pathology, including Ibex Prostate Detect, assisting pathologists in detecting cancer and quantifying tissue features.
Our summary of the vendor’s positioning — verbatim claim not yet recordedWhat we found
Level 2 · augmentative
Completes the unit of work end to end without a person producing it, but a radiologist must sign the report; FDA clearances in this category are for assistive use. That checkpoint is imposed from outside the product, not configured within it.
The human checkpoint here is imposed by regulation — it is not a setting that can be turned off.
Graded 2026-08-01 · re-check 2026-11-01
Procurement detail
- Deployment
- saasvendor documentation
- Compliance
- HIPAA · FDA-cleared (Ibex Prostate Detect)report dates not disclosed — request before signing
- Integrations
- Digital pathology scanners claim unverifiedlab information systems claim unverified
- Pricing
- platform-licenseNot publicly listed.
- Human checkpoint
- Requiredregulatory, not configurable
- Named customers
- European and US pathology labs (not individually named)from cited sources
Will they still be here?
- Funding
- Privately held; specific 2026 funding figures not confirmed in available sources
- Founded
- 2016
- HQ
- Tel Aviv, Israel
Sources
Logo retrieved 2026-08-01from the vendor’s own site · trademark of Ibex Medical Analytics Ltd.
- insideprecisionmedicine.comIndependent · retrieved 2026-08-01
- pmc.ncbi.nlm.nih.govIndependent · retrieved 2026-08-01
Where it’s weak
Smaller scale and less US market penetration than PathAI/Paige.
Corrections
Vendors may submit factual corrections free of charge. We correct facts and publish the change. We do not accept payment to change a grade. Submit a correction →